AML is associated with a wide range of genetic alterations, including mutations in receptor tyrosine kinases (RTKs) that perturb intracellular signaling networks which play a role in leukemia pathogenesis and are manifested in the clinical heterogeneity of the disease. Here, NTRK1 is linked to acute myeloid leukemia.